Published in Stat Med on September 10, 2013
Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials. Ann Oncol (2015) 0.85
Adaptive Phase I clinical trial design using Markov models for conditional probability of toxicity. J Biopharm Stat (2015) 0.83
Early phase clinical trials to identify optimal dosing and safety. Mol Oncol (2014) 0.78
Innovations for phase I dose-finding designs in pediatric oncology clinical trials. Contemp Clin Trials (2016) 0.76
Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid Tumours. Sci Rep (2016) 0.75
Challenges and Innovations in Phase I Dose-Finding Designs for Molecularly Targeted Agents and Cancer Immunotherapies. J Biom Biostat (2016) 0.75
Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93
Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med (2003) 12.23
Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS (2003) 5.61
Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA (2010) 5.04
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS (2007) 4.31
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest (2009) 2.92
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil (2010) 2.70
Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS (2009) 2.50
Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. Lancet (2007) 2.37
Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines. Clin Infect Dis (2011) 2.30
Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis (2009) 2.26
Carriage of methicillin-resistant Staphylococcus aureus in home care settings: prevalence, duration, and transmission to household members. Arch Intern Med (2009) 2.07
Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS (2008) 2.01
Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination. Proc Natl Acad Sci U S A (2013) 2.00
Counterfactual links to the proportion of treatment effect explained by a surrogate marker. Biometrics (2005) 1.98
Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst (2013) 1.90
Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen. J Infect Dis (2002) 1.90
Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature. Eur J Cancer (2011) 1.85
Effectiveness of disease-management programs for improving diabetes care: a meta-analysis. CMAJ (2010) 1.66
Continual reassessment method for ordered groups. Biometrics (2003) 1.60
Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. AIDS (2008) 1.56
Breast cancer risk in relation to abortion: Results from the EPIC study. Int J Cancer (2006) 1.51
Regulation of peritoneal and systemic neutrophil-derived tumor necrosis factor-alpha release in patients with severe peritonitis: role of tumor necrosis factor-alpha converting enzyme cleavage. Crit Care Med (2005) 1.51
Non-parametric optimal design in dose finding studies. Biostatistics (2002) 1.51
Leukocyte activation: the link between inflammation and coagulation during heatstroke. A study of patients during the 2003 heat wave in Paris. Crit Care Med (2008) 1.50
Methodological issues of non-inferiority trials in HIV-infected patients: a need for consensus? AIDS (2008) 1.48
Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? J Clin Oncol (2011) 1.48
CD4 natural history and informative censoring in Sub-Saharan Africa. J Acquir Immune Defic Syndr (2006) 1.41
On the validity of meta-analyses: exhaustivity must be warranted, exclusion of duplicate patients too. J Clin Epidemiol (2010) 1.39
Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trials. Biometrics (2009) 1.31
Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. Eur J Cancer (2013) 1.24
Emergency circulatory support in refractory cardiogenic shock patients in remote institutions: a pilot study (the cardiac-RESCUE program). Eur Heart J (2012) 1.23
Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol (2010) 1.22
Quantifying thymic export: combining models of naive T cell proliferation and TCR excision circle dynamics gives an explicit measure of thymic output. J Immunol (2009) 1.20
Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann Med (2002) 1.17
Decrease in circulating dendritic cells predicts fatal outcome in septic shock. Intensive Care Med (2006) 1.16
Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial. Target Oncol (2012) 1.13
Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. Int J Epidemiol (2012) 1.11
Successful long-term program for controlling methicillin-resistant Staphylococcus aureus in intensive care units. Intensive Care Med (2005) 1.11
Effect of age on immunological response in the first year of antiretroviral therapy in HIV-1-infected adults in West Africa. AIDS (2012) 1.11
Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials. Qual Life Res (2008) 1.08
Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France. AIDS (2008) 1.07
A novel approach for biomarker selection and the integration of repeated measures experiments from two assays. BMC Bioinformatics (2012) 1.05
First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration. AIDS (2010) 1.01
Pediatric human immunodeficiency virus infection and circulating IgD+ memory B cells. J Infect Dis (2008) 1.01
Sensitivity analysis when data are missing not-at-random. Epidemiology (2011) 1.01
Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine Cohort, France. Clin Infect Dis (2005) 0.98
Primary resistance to enfuvirtide (T20) in recently HIV-1 infected, antiretroviral-naive patients from the ANRS Aquitaine Cohort. Antivir Ther (2007) 0.97
Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells. J Antimicrob Chemother (2010) 0.97
Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load. Eur J Immunol (2014) 0.97
Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort. J Antimicrob Chemother (2009) 0.96
The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma. J Hepatol (2012) 0.94
Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients. Antimicrob Agents Chemother (2007) 0.94
Quantification of the relative importance of CTL, B cell, NK cell, and target cell limitation in the control of primary SIV-infection. PLoS Comput Biol (2011) 0.92
Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting. J Hepatol (2010) 0.91
Characteristics of HIV-2 and HIV-1/HIV-2 Dually Seropositive Adults in West Africa Presenting for Care and Antiretroviral Therapy: The IeDEA-West Africa HIV-2 Cohort Study. PLoS One (2013) 0.91
Development of anti-cancer drugs. Discov Med (2010) 0.90
Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agents. PLoS One (2012) 0.90
Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study). Antivir Ther (2008) 0.89
Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents. Target Oncol (2010) 0.89
Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field. Clin Trials (2010) 0.89
Comparison of early CD4 T-cell count in HIV-1 seroconverters in Côte d'Ivoire and France: the ANRS PRIMO-CI and SEROCO cohorts. J Acquir Immune Defic Syndr (2010) 0.88
Behavioral audiometry: validity of audiometric measurements obtained using the "Delaroche protocol" in babies aged 4--18 months suffering from bilateral sensorineural hearing loss. Int J Pediatr Otorhinolaryngol (2006) 0.87
Effect of intermittent interleukin-2 therapy on CD4+ T-cell counts following antiretroviral cessation in patients with HIV. AIDS (2012) 0.86
Impaired smooth pursuit in schizophrenia results from prediction impairment only. Biol Psychiatry (2010) 0.84
Tension-free vaginal tape and associated procedures: a case control study. Eur Urol (2004) 0.84
HIV type-1 transmission dynamics in recent seroconverters: relationship with transmission of drug resistance and viral diversity. Antivir Ther (2009) 0.83
The role of mannose-binding lectin in susceptibility to infection in preterm neonates. Pediatr Res (2008) 0.83
A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer. PLoS One (2012) 0.82
Options for clinical trials of pre and post-natal treatments for congenital toxoplasmosis. Mem Inst Oswaldo Cruz (2009) 0.82
Treatment monitoring of HIV-infected patients based on mechanistic models. Biometrics (2012) 0.82
Pravastatin in HIV-infected patients treated with protease inhibitors: a placebo-controlled randomized study. HIV Clin Trials (2007) 0.81
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer. Invest New Drugs (2003) 0.81
NIMROD: a program for inference via a normal approximation of the posterior in models with random effects based on ordinary differential equations. Comput Methods Programs Biomed (2013) 0.80
Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection. Antivir Ther (2006) 0.80
Ribavirin plasma concentration predicts sustained virological response to peginterferon Alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients. J Acquir Immune Defic Syndr (2009) 0.80
Prediction of cytomegalovirus (CMV) plasma load from evaluation of CMV whole-blood load in samples from renal transplant recipients. J Clin Microbiol (2007) 0.79
Dealing with missing data in the Center for Epidemiologic Studies Depression self-report scale: a study based on the French E3N cohort. BMC Med Res Methodol (2013) 0.79
Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/microl? Impact on immunovirological parameters. J Med Virol (2005) 0.78
Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings. BMC Infect Dis (2012) 0.78
Shelf life of predosed plates containing mefloquine, artemisinin, dihydroartemisinin, and artesunate as used for in vitro Plasmodium falciparum susceptibility assessment. J Clin Microbiol (2007) 0.78
Mathematical modelling of HIV prevention intervention. AIDS (2013) 0.78
Operating characteristics of two independent sample design in phase I trials in paediatric oncology. Eur J Cancer (2010) 0.78
Bone marrow histopathologic and molecular staging in epidermotropic T-cell lymphomas. Am J Clin Pathol (2003) 0.77
Cytokine and gene transcription profiles of immune responses elicited by HIV lipopeptide vaccine in HIV-negative volunteers. AIDS (2013) 0.77
A new endpoint definition improved clinical relevance and statistical power in a vaccine trial. J Clin Epidemiol (2009) 0.77
Recent developments in clinical trial designs for HIV vaccine research. Hum Vaccin Immunother (2015) 0.77
Serious psychiatric outcome of subjects prenatally exposed to diethylstilboestrol in the E3N cohort study. Psychol Med (2007) 0.77
Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy. BMC Med Res Methodol (2008) 0.76
Critical evaluation of disease stabilization as a measure of activity of systemic therapy: lessons from trials with arms in which patients do not receive active treatment. J Clin Oncol (2013) 0.76
Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev (2007) 0.75
Score tests for exploring complex models: application to HIV dynamics models. Biom J (2010) 0.75
Joint modeling of the clinical progression and of the biomarkers' dynamics using a mechanistic model. Biometrics (2011) 0.75
np1: a computer program for dose escalation strategies in phase I clinical trials. Comput Methods Programs Biomed (2007) 0.75
Discussion on the effect of age on immunological response in the first year of antiretroviral therapy in HIV-1-infected adults. AIDS (2013) 0.75
Treatment of dyslipidaemia in HIV-infected persons. Expert Opin Pharmacother (2005) 0.75
[What is the contribution of tumor response in colorectal cancer?]. Bull Cancer (2013) 0.75